Mereo Biopharma
Mereo Biopharma Group plc, commonly referred to as Mereo Biopharma, is a pioneering biopharmaceutical company headquartered in Great Britain. Founded in 2015, the company focuses on developing innovative therapies for patients with rare diseases and unmet medical needs, particularly in the fields of oncology and metabolic disorders. Mereo Biopharma's core products, including its unique therapeutic candidates, are designed to address significant gaps in current treatment options, showcasing the company's commitment to advancing healthcare. With a strong emphasis on clinical development, Mereo has achieved notable milestones, including successful clinical trials that position it as a key player in the biopharma industry. As it continues to expand its operational reach, Mereo Biopharma is dedicated to delivering transformative solutions that enhance patient outcomes and solidify its market presence.
DitchCarbon Score
How does Mereo Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mereo Biopharma's score of 3 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mereo Biopharma's reported carbon emissions
Mereo Biopharma, headquartered in Great Britain, has reported its carbon emissions data for the years 2020 to 2022. In 2020, the company had an emissions intensity of approximately 730 kg CO2e per employee. This figure decreased to about 490 kg CO2e per employee in 2021, and further reduced to approximately 460 kg CO2e per employee in 2022. Despite these reductions in emissions intensity, Mereo Biopharma has not disclosed specific total emissions figures or set formal reduction targets under the Science Based Targets initiative (SBTi). The company has not made any public climate pledges, indicating a potential area for future commitment. Overall, while Mereo Biopharma has shown a positive trend in reducing emissions per employee, the absence of comprehensive emissions data and formal reduction targets suggests that there is room for improvement in their climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mereo Biopharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
